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Abstract 8 Tumors expressing programmed death ligand 1 (PD-L1) inter-9
act with the corresponding negative-signal generating immune 10 receptor on the surface of CD8 T cells, PD-1, thereby suppressing 11 antitumor activity. Therapeutics blocking this interaction have 12
shown promise in various cancers by restoring functional anti-13
tumor T-cell activity. We explored the degree of PD-L1, PD-1, and 14
CD8 expression in a retrospective analysis of 29 clinical synovial 15 sarcoma samples. Quantitative immunohistochemistry and mul-16 tiplex immunofluorescence Q5 were used to determine relative quan-17 tification of CD8 þ and PD-1 þ T cells and PD-L1 expression within 18 the intratumor area and the interface between the tumor and the 19 surrounding nontumor tissue (i.e., invasive margin), and colo-20 calization of these factors, respectively. PD-L1, PD-1, and CD8 22 cell densities in the tumor-invasive margins were significantly 23 higher in the metastatic tumors than the primary tumors (P < 24 0.01), and PD-L1, PD-1, and CD8 cell densities were all signif-25 icantly positively correlated with one other (P < 0.0001). PD-1 26 cell density in the tumor-invasive margin was significantly asso-27 ciated with worse progression-free survival. Multiplex immuno-28 fluorescence demonstrated coexpression of PD-1 and CD8 on 29 lymphocytes within the invasive margin, as well as relative 30 proximity between PD-1 þ CD8 cells and PD-L1 þ tumor cells.
31 Our results provide a preclinical rationale for screening of 32 patients with synovial sarcoma for the colocalization of CD8, 33 PD-1, and PD-L1, which may be a marker for response to PD-1 34 blockade therapy. Cancer Immunol Res; 5(2); 1-11. Ó2016 AACR. 35 36 Introduction
37
Synovial sarcoma is an aggressive mesenchymal neoplasm 38 with variable epithelial features, which accounts for 5% to 39 10% of all soft-tissue sarcomas (1) . It chiefly affects older 40 children and younger adults, and can occur at virtually any 41 anatomic site. Clinical outcomes remain poor, with 5-year and 42
10-year survival rates of 60% and 50%, respectively (1, 2) . Fifty 43 percent of patients with synovial sarcoma patients develop 44 metastases, primarily to the lungs or pleura, and have signifi-45 cantly worse clinical outcomes (1) (2) (3) . Synovial sarcoma has 46 a propensity for late recurrence and metastasis (occurring after 48 5 years), and 10 year minimum follow-up is generally recom-49 mended (1) . Standard treatment for synovial sarcoma primarily 50 consists of surgical resection, radiotherapy, and chemotherapy 51 with alkylating agents, topoisomerase inhibitors, and anthracy-52 clines. Although response rates of approximately 50% have been 53 reported for these types of chemotherapy regimens, patients with 54 refractory or recurrent/metastatic disease have few viable treat-55 ment options and none with proven improvements in survival 56 (1, 2) . The limitations in current treatment for synovial sarcoma 57 make the development of new therapeutics a pressing concern, 58 particularly for cases with metastatic disease.
59 The great majority (70%-80%) of synovial sarcomas express 60 the cancer-testis antigen NY-ESO-1 (New York esophageal squa-61 mous cell carcinoma 1), which is encoded by the CTAG1B gene.
62 This has allowed the successful clinical testing of a therapeutic 63 approach targeting T cells specific for NY-ESO-1, with the use of 64 adoptive cell therapy (ACT). ACT involves the generation of large 65 quantities of CD8 T cells directed against specific tumor antigens. 66 NY-ESO-1-specific T cells can be generated either by ex vivo 67 expansion of endogenous, low-frequency NY-ESO-1-specific 68 CD8 T cells, which are then re-infused into the patient (4, 5), or 69 by ex vivo genetic modification of peripheral mononuclear blood 70 cells, in which they are transduced with a T-cell receptor (TCR) 71 directed against NY-ESO-1, expanded, and re-infused into the 72 patient (6). Tumor vaccines have also been an effective means of 73 stimulating patients' dendritic cells to help generate T-cell activity 74 directed against NY-ESO-1 (7). Clinical trials involving NY-ESO-75 1-directed ACT against synovial sarcoma have shown promise in 76 achieving objective clinical responses in patients with metastatic 77 or refractory disease (6). These therapies, although not FDA-78 approved, are therefore increasingly attractive treatment choices 81 for metastatic and refractory synovial sarcoma and underscore the 82 inherent immunogenicity of this malignancy and the need to 83 further enhance therapies that exploit this immunogenicity. 84
The experience with NY-ESO-1 ACT in synovial sarcoma high-85
lights that this is a tumor type that can be targeted effectively with 86
immunotherapies. It is possible that pre-existing T cells in syno-87 vial sarcomas could be inhibited by an immune checkpoint, and 88 releasing this inhibitory signal may result in antitumor activity. 89
Programmed cell death 1 (PD-1) and its corresponding ligand 90
PD-L1 have emerged as important immune checkpoints by which 91 cancer cells evade the host immune response. Under normal 92
conditions, PD-1 is expressed on activated CD8 þ T cells, and its 93
interaction with PD-L1 on host tissues leads to the inhibition of 94 TCR signaling, limits the interactions between T cells and target 95 cells, and ultimately leads to T-cell inactivation (8-11). PD-L1 96 expression is induced by localized inflammatory stimuli, such as 97
IFNs, which are released by tumor-infiltrating lymphocytes (9). 98
The PD-L1 induction process has been termed "adaptive immune 99
resistance" (12) and represents a mechanism by which cancer cells 100 protect themselves from immune- Pathology Core Laboratory, and 5-mm-thick serial sections were 138 generated for subsequent immunohistochemistry (IHC) and 139 multiplex immunofluorescence.
141

Immunohistochemistry staining
142 Serial sections from patient tumor samples were stained for NY-143 ESO-1, PD-L1, PD-1, and CD8 at the UCLA Anatomic Pathology 144 IHC Laboratory. Slides were deparaffinized and rehydrated with a 145 series of graded ethanols to deionized water. Antigen retrieval was 146 performed in Tris-EDTA at pH 9, and slides were cooked at high 147 pressure at 120 C for 5 minutes. Immunostaining was performed 148 on Leica Bond III autostainers using Leica Bond ancillary reagents 149 (Leica Biosystems). Antibodies used included anti-CD8 clone C8/ 150 144B (1/100, DAKO), anti-PD-L1 clone SP142 (1/200, Spring-151 Bio), or anti-PD-1 clone NAT105 (1/50, Cell Marque). Antigen-152 antibody binding was visualized via the REFINE polymer 3,3 0 153 diaminobenzidine (DAB) detection system (Lieca). Stained slides 154 were treated with 0.5% cupric sulfate for 10 minutes, then 155 counterstained with hematoxylin, and coverslipped for subse-156 quent analysis.
157 Synovial sarcoma tumor marker immunostainings were per-158 formed manually. Antibodies used included anti-NY-ESO-1 clone 159 E978 (1/200, pH 8 antigen retrieval, Santa Cruz Biotechnologies), 160 anti-Bcl-2 clone 124 (1/300, pH 8 antigen retrieval; DAKO), anti-161 CD99 clone 12E7 (1/100, pH 8 antigen retrieval; DAKO), and 162 anti-EMA clone E29 (1/500, pH 6 antigen retrieval; DAKO). For 163 the Bcl-2, CD99, and EMA antibodies, antigen binding was again 164 visualized via the REFINE polymer DAB detection system (Lieca).
165 For the NY-ESO-1 antibody, antigen binding was visualized using 166 biotinylated horse anti-mouse IgG antibody (Vector Laborato-167 ries), followed by agarose streptavidin (Vector Laboratories). DAB 168 and hydrogen peroxide were used as the substrates for the per-169 oxidase enzyme. All slides were counterstained with hematoxylin 170 and coverslipped for subsequent analysis. with a series of graded ethanols to deionized water. Antigen 205 retrieval was performed in Tris-EDTA at pH 9, and slides were 206 cooked at high pressure at 120 C for 15 minutes. Slides were 207 then serially stained with anti-PD-1 clone NAT105 (1/1,500; 208
Cell Marque), anti-PD-L1 clone SP142 (1/4,000; SpringBio), 209
anti-CD8 clone C8/144B (1/5,000, DAKO), or anti-TLE1 210 clone ab183742 (1/2,000; Abcam), which served as a specific 211
nuclear marker for synovial sarcoma tissue. Horseradish perox-212
idase-conjugated secondary labeling was performed using 213 SuperPicture Polymer detection system. Signal for individual 214 antibody complexes was labeled and visualized with FITC, Cy3, 215
Cy5, and Cy3.5 tyramide signal amplification kits (PerkinElmer), 216
individual primary/secondary antibody complexes were stripped 217 via microwave treatment, and the process was repeated for each 218 subsequent antibody labeling for a different antigen and fluor-219 ophore. Nuclei were visualized with Prolong Gold Antifade 220
Reagent with DAPI (Invitrogen), and slides were then cover-221 slipped for imaging. Stained slides were imaged using excitation 222
and emission spectra for each individual fluorophore, and 223 overlaid composite images were generated using the Vectra 255 patients with synovial sarcoma (12 primary lesions, 17 meta-256 static lesions) were selected for analysis. All metastatic samples 257 were derived from lung metastases. Table 1 and Fig. 1A and B 258 summarize data regarding the demographics, prior treatment, 259 and PFS or OS between the two groups. At 60 months, the OS 260 probabilities were 59.9% for all subjects, 78.6% for the patients 261 with primary sarcoma, and 44.0% for the patients with meta-262 static sarcoma, respectively. The 60-month PFS probabilities 263 were 53.3% for all subjects, 81.8% for the patients with primary 264 sarcoma, and 34.3% for the patients with metastatic sarcoma, 265 respectively. The metastatic disease population had a signifi-266 cantly higher incidence of prior chemotherapy than did the 267 primary disease population.
268
PD-1 expression in tumor-invasive margins correlated with 269 worse PFS survival 270 Biopsies were stained by IHC and analyzed using quantitative 271 digital pathology via the Indica Labs Halo platform as described 272 above (Fig. 2) . PD-1 cell density in the invasive margin niche was 273 significantly associated with worse PFS for all patients. The HR for 274 log 2 -transformed PD-1 density in the invasive margin was 1.62 275 based on univariate Cox proportional hazard regression analysis 276 (P ¼ 0.006). CD8 and PD-L1 invasive margin cell densities 277 approached, but did not achieve, statistically significant associa-278 tion with worse PFS, with HR values of 1.24 (P ¼ 0.082) and 1.21 279 (P ¼ 0.071), respectively. The association between CD8, PD-1, or 280 PD-L1 intratumor cell densities and PFS was not statistically 281 significant, nor was the association between CD8, PD-1, or PD-282 L1 invasive margin or intratumor cell densities and OS. No other 283 associations were significant between CD8, PD-1, and PD-L1 284 densities in the invasive margin or the intratumor niches with 285 patient age, gender, or prior treatment.
286
Metastatic synovial sarcomas had increased PD-L1, PD-1, 287 and CD8 in invasive margins 288 Using the Halo image analysis platform to quantify cell den-289 sities within intratumor and invasive margin niches (data sum-290 marized in Table 2 ), we determined that PD-L1, PD-1, and 291 CD8 cell densities in the tumor-invasive margins were all signif-292 icantly higher in the metastatic tumors compared with the pri-293 mary tumors (Fig. 3A) . Furthermore, PD-L1, PD-1, and CD8 294 cell densities were all significantly positively correlated with 295 one other within the invasive margin niche (Fig. 3B) . Within 296 the invasive margin niche, we observed positive correlation 297 between cell density values for PD-1 with CD8 (r ¼ 0.76, P < 298 0.0001), PD-L1 with CD8 (r ¼ 0.71, P < 0.0001), and PD-L1 with with the primary tumors ( Fig. 3C ). Although the CD8 and PD-1 304
cell densities trended higher in the intratumor niche of the 305 metastatic tumors as compared with the primary tumors, the 307 differences did not achieve statistical significance (P ¼ 0.11 and P 308 ¼ 0.08, respectively). However, we still observed a similarly 309 striking positive correlation between PD-1 with CD8 (r ¼ 0.72, 310 P < 0.0001), PD-L1 with CD8 (r ¼ 0.58, P <0.01), and PD-L1 with 311 PD-1 (r ¼ 0.63, P < 0.001) cell densities within the intratumor 314 niche ( Fig. 3D ). NY-ESO-1 density was not correlated with CD8, 315 PD-1, or PD-L1 densities in either the invasive margin or intra-316 tumor niches (data not shown).
317
Multiplex immunofluorescence was used to confirm that the 318 increased PD-L1 and PD-1 expressions in the tumor-invasive 319 margins were present on the synovial sarcoma tumor cells and 320 the CD8 T cells, respectively. This technique enables the serial 322 fluorescent labeling of multiple proteins within a single-tissue 323 slide. Coexpression of PD-1 and CD8 was demonstrated on 324 lymphocytes present within the tumor-invasive margins, as well 325 as qualitative proximity between PD-1 þ cells and PD-L1 þ tumor 326 cells. PD-L1 was expressed on tumor cells, which were distin-327 guished by the presence of synovial sarcoma-specific TLE1 nucle-328 ar staining (Fig. 4) . Once the tumor border has been established, a perimeter of 400-mm thickness is established via concentric partitioning, consisting of 50% intratumor space and 50% extra-tumor space. This perimeter (the area between the two green lines) is defined as the tumor-invasive margin. CD8, PD-1, and PD-L1 cell density analyses are then performed in serial sections for both the intratumor and the invasive margin niches, with cell density reported as number of positive cells/mm 2 . Cells marked yellow are scored as positive, whereas cells marked blue are scored as negative. Magnification, Â80. Given the grim prognosis and lack of efficacious treatment 333 options for metastatic synovial sarcoma, the exploration of novel 335 therapeutics for this malignancy is of ample interest. The recent 336 widespread success of T-cell-based immunotherapy for multiple 337 other cancers, specifically via PD-1/PD-L1 inhibition, has Figure 3 . A, Relative CD8, PD-L1, and PD-1 cell densities in the invasive margins of all samples of synovial sarcoma. PD-L1, PD-1, and CD8 cell densities were all significantly higher in the invasive margins of metastatic compared with primary tumors ( ÃÃ , P < 0.01; ÃÃÃ , P < 0.0001). Error bars represent SDs. B, Spearman correlation plots demonstrating that CD8, PD-L1, and PD-1 cell densities all positively correlate with one another within both the invasive margins. C, Relative CD8, PD-L1, and PD-1 cell densities in the intratumor margins of all samples of synovial sarcoma. PD-L1 cell densities were significantly higher in the intratumor niche of metastatic compared with primary tumors ( ÃÃ , P < 0.01). D, Spearman correlation plots demonstrating that CD8, PD-L1, and PD-1 cell densities all positively correlate with one another within the intratumor niches.
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Cancer Immunology Research 6 generated hope that these techniques could be applied to synovial 341 sarcomas, as well as other soft-tissue malignancies. 342
Our data show that PD-L1 is expressed in synovial sarcoma, 343
predominantly in lung metastases. This increased PD-L1 344 expression is proximally associated with increased concentra-345 tions of CD8 TILs expressing PD-1 in the tumor-invasive 346 margin. It is known that PD-1 can be expressed on numerous 347
cell types in addition to CD8 T cells, including B cells (20); PD-348 L1 expression has also been reported in dendritic cells, macro-349 phages, plasma cells, and B cells (20-23). It is possible that the 350 minority of cells observed expressing PD-L1 without TLE1, or 351
PD-1 without CD8, may represent associated expression with 352 any of these other cell types.
353
Our data showed that increased expressions of PD-L1, PD-1, 354
and CD8 are directly correlated with one another. In several cases, 355 PD-L1 expression was substantially higher than the associated 356 PD-1 and CD8 expression densities ( Fig. 3B and D) . As PD-L1 can 357 be either constitutively expressed or induced via localized inflam-358 matory stimuli within the tumor microenvironment, such as IFNs 359
(24-26), it may be that a subset of tumors have preexisting 360 constitutive expression of PD-L1 in addition to induction by 361 inflammatory stimuli. Alternatively, they may represent a subset 362 of synovial sarcomas that are more sensitive to inflammatory 363 stimuli, resulting in a more dramatic PD-L1 induction. Further 364 studies at the genomic and transcriptomic levels are needed to 365 fully elucidate the significance of such tumors as they pertain to 366 potential responsiveness inflammatory stimuli and PD-1/PD-L1 367 inhibition.
369 These expression patterns of PD-L1 in close proximity to PD-1-370 positive CD8 TILs at the invasive margin are analogous to what 371 our group has previously reported with melanoma (19), and what 372 others have reported in other malignancies as well, including 373 other sarcoma subtypes, such as gastrointestinal stromal tumors, 374 osteosarcoma, and chondrosarcoma (25, (27) (28) (29) . D'Angelo and 375 colleagues previously reported a study of PD-L1, PD-1, and CD8 376 expression patterns in a large number of sarcoma subtypes (29) .
377 Although their study reported no significant expression of PD-L1, 378 PD-1, or CD8 in synovial sarcoma, they only studied a very small 379 number of samples from that malignancy (n ¼ 5), their study did 380 not distinguish between primary and metastatic tumor samples, 381 and it did not specifically focus in the area of the tumor with most 382 interest, the invasive margin. In our study, the higher incidence of 383 prior chemotherapy was not associated with different PD-L1, PD-384 1, or CD8 expression. However, we found that PD-1 density in the 385 tumor-invasive margin was significantly associated with lower 386 PFS, and CD8 and PD-L1 densities in the invasive margin also 387 approached significance in this association, as well. This phe-388 nomenon has been studied in multiple cancer subtypes, with PD-389 1 or PD-L1 expression levels being associated with either favorable 390 or unfavorable impacts on PFS or OS, depending on the cancer 391 type studied (30) (31) (32) (33) . Further prospective studies are needed to 392 further explore and validate these associations, as well as further 393 study how such expression patterns would predict responsiveness 394 to PD-1/PD-L1 inhibitor therapy.
395 Given that our prior experience with melanoma demonstrated 396 that the presence of CD8 TILs at the tumor-invasive margin (along with concomitant proximal PD-1 and PD-L1 induction) predicted 400 clinical response to PD-1 inhibition, it is reasonable to extrapolate 401 that this pattern might predict clinical response to PD-1 inhibition 402 in other tumor types as well. SARC 028 is an ongoing phase II 403 clinical trial exploring the use of the pembrolizumab (an antibody 404
to PD-1) in multiple sarcoma subtypes, including synovial sar-405 coma (34). It would be of great interest to correlate any clinical 406 responses of synovial sarcoma patients with pre-existing CD8 407
infiltration and concomitant proximal PD-1 and PD-L1 expres-408 sion. We have found no correlation between NY-ESO-1 density 409 and CD8, PD-1, or PD-L1 density in either the invasive margin or 410
intratumor niches. It may be that NY-ESO-1 is not a sufficiently 411 strong enough antigen to provoke a significant CD8 T-cell 412 response in itself. There may also be fundamental differences in 413 certain subtypes of synovial sarcoma which render them more 414 sensitive or resistant to a CD8 T-cell response. Spranger and 415
colleagues previously reported an inverse relationship between 416 melanoma-intrinsic b-catenin signaling and intratumoral T-cell 417
infiltration (35, 36) . Given that b-catenin induction has been 418 documented in synovial sarcoma cases with particularly poor 419
prognoses (37, 38) , it may be that this or other factors may 420
contribute to the baseline TIL activity which might be present in 421 a given tumor. Further studies at the genomic and transcriptomic 422 levels may reveal baseline tumor mutations, as well as novel 423
tumor antigens or neoepitopes resulting from nonsynonymous 424 mutations, which collectively are responsible for the immunoge-425 nicity of certain subsets of synovial sarcoma. However, a lack of 426 pre-existing CD8, PD-1, or PD-L1 induction might not preclude 427 the use of PD-1 inhibitors in synovial sarcoma, due to the high 428 exploitability of this malignancy for adoptive cell therapy directed 429
at NY-ESO-1. Patients without a pre-existing CD8 infiltrate could 430 be provided one via adoptive cell therapy, which could then be 431 combined with anti-PD-1 therapy to perpetuate the inherently 432 limited duration of initially robust antitumor activity of this 433 therapeutic modality. Alternatively, if endogenous T cells are 434 already present in a given tumor, but their activation is blocked 435
by PD-1/PD-L1 interactions, they may simply need to be 436 unleashed in situ, as opposed to requiring the ex vivo manipulation 437 of T cells.
438
Our study has several limitations. First, as our study was based 439 on a retrospective analysis of synovial sarcoma tumors, we could 440 not define a critical threshold of PD-L1, PD-1, or CD8 cell density 441 required for a therapeutic response to PD-1/PD-L1 blockade. 442
Additional studies in the future might identify expression thresh-443 olds linked to improved treatment responses. Furthermore, 444
although the Aperio scans of the brightfield IHC slides enabled 445 whole slide visualization with the ability to zoom in gradually up 446 to 200x, the Vectra imaging system used for multiplex immuno-447 fluorescence imaging only permitted direct visualization using 448
200x total magnification. As such, we were unable to obtain whole 449 slide images and subject them to the same whole slide analysis 450
with the Indica Labs Halo platform that was used for the bright-451
field IHC. Finally, our analysis methods utilized serial slides 452 derived from primary tumor resection or wedge resections of 453 lung metastases of synovial sarcoma tumors instead of tissue 454 microarrays, which we felt would not allow for accurate visual-455
ization of the tumor-invasive margin with the surrounding nor-456 mal tissue. Although whole tumor or wedge resection analysis 457 allows for a more complete representation of PD-L1, PD-1, or 458
CD8 density variations within the tumor-invasive margin, we 459 recognize that prospective wedge resection and subsequent anal-461 ysis of lung metastases to determine likelihood of treatment 462 success with PD-1/PD-L1 inhibitors may not be technically fea-463 sible in every patient.
464 In summary, our results provide preclinical rationale for 465 screening of patients with synovial sarcoma for this pattern of 466 PD-L1/PD-1 induction in the setting of CD8 T-cell infiltration, 467 as well as possible treatment of patients with synovial sarcoma 468 with PD-1/PD-L1 inhibitors, especially in patients with meta-469 static disease, who often have few treatment options. Patients 470 who do not have a pre-existing CD8 infiltrate could potentially 471 be given one via adoptive cell therapy, which could then be 472 combined with PD-1/PD-L1 inhibition for enhanced therapeu-473 tic response. 
